MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Infectious Disease_Hepatitis
Regulus Therapeutics Inc. (NASDAQ: RGLS)*
Organization & Developments: Regulus
Parents
Regulus Therapeutics Inc. (NASDAQ: RGLS)*
Children
*A strategy which might be useful in treating complex diseases like diabetes or autoimmunity
*Biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs.
*Biopharmaceutical company leading the discovery and development of innovative new medicines targeting microRNAs.
*MRNAi are thought to hold huge potential as therapeutics, because they can affect not just one gene or protein in isolation, but full networks of genes
*Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field.
2008: *Alnylam–Isis Venture Regulus, Leader in MicroRNA Drugs, Aspires to Create New Paradigm of Treatments (2008)
2011: Regulus Gets License From NYU (2011)
2011: Regulus, the MicroRNA Child of Alnylam and Isis, Offers Litmus Test for Biotech Hope in 2011
2016: Biotech Forum Daily Digest: Brexit Impacts Continue, Xencor's Huge Deal, Major Approval For Gilead
2016: Should Gilead Investors Fear Regulus? - Gilead Sciences, Inc. (NASDAQ:GILD)
2017: Regulus bails on HCV candidate RG-101; shares down 35% premarket - AstraZeneca Group plc (NYSE:AZN)
2024: Regulus: It Is Finding Its Stride Despite Initial Setback In Targeting ADPKD
2025: Novartis to buy kidney-focused Regulus for $800 million upfront
2025: Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG
2025: Regulus Therapeutics: An Undervalued Buy, With A $0.90 CVR And A $7 Payout
Jumps
*Key People: Regulus
Finance & Acquisitions: Regulus